Page last updated: 2024-09-04

tipifarnib and losartan potassium

tipifarnib has been researched along with losartan potassium in 3 studies

Compound Research Comparison

Studies
(tipifarnib)
Trials
(tipifarnib)
Recent Studies (post-2010)
(tipifarnib)
Studies
(losartan potassium)
Trials
(losartan potassium)
Recent Studies (post-2010) (losartan potassium)
309929424,3902,4935,408

Protein Interaction Comparison

ProteinTaxonomytipifarnib (IC50)losartan potassium (IC50)
Bile salt export pumpHomo sapiens (human)8.53
Type-1A angiotensin II receptor Rattus norvegicus (Norway rat)0.0082
Type-1B angiotensin II receptorRattus norvegicus (Norway rat)0.0049
Type-2 angiotensin II receptorRattus norvegicus (Norway rat)0.0082
5-hydroxytryptamine receptor 1AMus musculus (house mouse)0.0082
Type-1 angiotensin II receptorCavia porcellus (domestic guinea pig)0.018

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gabrilove, JL1
Cassinat, B; Chomienne, C; Gervais, N; Larghero, J; Padua, RA; Rain, JD; Rousselot, P; Schlageter, MH1
Odenike, O; Tefferi, A1

Reviews

2 review(s) available for tipifarnib and losartan potassium

ArticleYear
Cancer therapy. New strategies and treatment modalities for optimizing patient outcomes.
    Seminars in hematology, 2001, Volume: 38, Issue:3 Suppl 7

    Topics: Alkyl and Aryl Transferases; Anemia; Enzyme Inhibitors; Erythropoietin; Farnesyltranstransferase; Humans; Neoplasms; Quinolones; Recombinant Proteins

2001
Conventional and new treatment options for myelofibrosis with myeloid metaplasia.
    Seminars in oncology, 2005, Volume: 32, Issue:4

    Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents; Azacitidine; Benzamides; Chronic Disease; Decitabine; Erythropoietin; Humans; Imatinib Mesylate; Piperazines; Primary Myelofibrosis; Pyrimidines; Quinolones; Recombinant Proteins

2005

Other Studies

1 other study(ies) available for tipifarnib and losartan potassium

ArticleYear
Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells.
    Blood, 2005, May-01, Volume: 105, Issue:9

    Topics: Alkyl and Aryl Transferases; Case-Control Studies; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Erythroid Precursor Cells; Erythropoiesis; Erythropoietin; Farnesyltranstransferase; Humans; Polycythemia Vera; Quinolones

2005